AZ Cares India

Total HCPs

1,247

Across 8 territories

Tier 1 Doctors

186

↑ 12 this month

Active Prescribers

418

Rx in last 30 days

Dormant HCPs

203

No Rx in 60+ days

NBRX Trend — last 6 months

Combined brands

Tagrisso

Enhertu

Adoption Funnel

HCP engagement to repeat prescribers

Engaged HCPs847

First Rx placed561

Repeat prescribers418

Top prescribers by NBRX

Click any row to open HCP detail

HCP	Territory	Specialty	Tier	Tagrisso Rx	Enhertu Rx	Total NBRX	vs Last Month
Dr. Priya Mehta	Mumbai North	Med. Oncology	Tier 1	28	14	42	↑ 18%
Dr. Arjun Kapoor	Delhi NCR	Pulmonology	Tier 1	35	0	35	→ 0%
Dr. Rahul Sharma	Hyderabad	Hemato-Onco	Tier 2	18	12	30	↑ 25%
Dr. Mehul Desai	Ahmedabad	Thoracic Onco	Tier 2	24	0	24	↓ 8%
Dr. Sunita Rao	Bangalore	Med. Oncology	Tier 2	0	18	18	↑ 12%
Dr. Ravi Iyer	Pune	Med. Oncology	Tier 3	14	4	18	→ 3%

PM

Dr. Priya Mehta

Both Brands Tier 1

Medical Oncologist · Sir H.N. Reliance Foundation Hospital, Mumbai

NSCLC HER2+ Breast Gastric/GEJ ZBM: Sneha Patil · Territory: Mumbai North · HCP-00341

Total NBRX (YTD)

42

First Tagrisso Rx

Jan 12, 2024

First Enhertu Rx

Aug 5, 2024

PAP Enrolments

7 patients

Avg Rx Frequency

18 days

Dropout Rate

14%

Rx Volume Trend

Monthly NBRX · both brands

Tagrisso

Enhertu

Rx by Indication

YTD prescription split

NSCLC (Tagrisso)

22 52%

HER2+ Breast (Enhertu)

14 33%

Gastric/GEJ (Enhertu)

6 15%

Dosage & Regimen

Prescribed doses per indication

Brand	Indication	Dose	Rx	Share
Tagrisso	NSCLC 1st line (EGFR+)	80mg OD	18	82%
Tagrisso	NSCLC 2nd line (T790M)	80mg OD	4	18%
Enhertu	HER2+ Breast (high expr.)	5.4mg/kg	10	71%
Enhertu	HER2+ Breast (low expr.)	5.4mg/kg	4	29%
Enhertu	Gastric/GEJ (HER2+)	6.4mg/kg	6	100%

Indication Depth

NSCLC — EGFR+

Tagrisso · 1st & 2nd line

22 Rx

1st line (80mg OD)

18

2nd line (T790M)

4

HER2+ Breast Cancer

Enhertu · 5.4mg/kg Q3W

14 Rx

HER2 high expr.

10

HER2 low expr.

4

Gastric / GEJ Cancer

Enhertu · 6.4mg/kg Q3W

6 Rx

HER2+ gastric

6

Prescribing Frequency

Time between repeat orders

Avg gap (Tagrisso)

16d

Avg gap (Enhertu)

22d

Longest gap seen

41d

Orders this month

6

Gap distribution — 2025

New vs Continuation Rx

Patient type split — YTD

New patients

26

62% of total Rx

Continuation Rx

16

38% of total Rx

Split by brand

Tagrisso

67%

33%

Enhertu

50%

New

Continuation

Patient Dropout Rate

Discontinuation by indication

14%

Overall YTD dropout

Tagrisso — NSCLC 1st line8%

Tagrisso — NSCLC 2nd line22%

Enhertu — HER2+ Breast18%

Enhertu — Gastric/GEJ25%

White Space Opportunity

342

Doctors on 1 brand only

Tagrisso Only

214

Enhertu not started

Enhertu Only

128

Tagrisso not started

Dual Brand Prescribers

204

↑ 22 this quarter

Tagrisso only

214

Tagrisso

High-value Tier 1 & 2 doctors active on Tagrisso with zero Enhertu Rx. Primary cross-sell priority for field teams.

Enhertu only

128

Enhertu

Oncologists with HER2+ focus not yet introduced to Tagrisso NSCLC clinical data. Strong scientific case to make.

Both brands

204

Both

Fully activated doctors. Focus on share of wallet, volume deepening, and referral network activation.

No Rx — dormant

701

Dormant

Received engagements but no prescription placed. Barrier investigation needed by ZBM.

Priority cross-sell list — Tagrisso → Enhertu

Tier 1 & 2 Tagrisso prescribers with zero Enhertu Rx

HCP	Territory	Tagrisso Rx (YTD)	Last Tagrisso Rx	Enhertu Status	Engagements YTD	Priority
Dr. Arjun Kapoor	Delhi NCR	35	Apr 2	Not started	3	High
Dr. Mehul Desai	Ahmedabad	24	Mar 20	Not started	2	High
Dr. Ravi Iyer	Pune	19	Mar 30	Not started	4	Medium
Dr. Sneha Kulkarni	Nagpur	15	Apr 1	Not started	1	Medium

YTD Actual Patients

804

vs 930 planned (Q1)

YTD Compounded Gap

–126

Carried into Apr target

Territories on Track

5/8

↑ 1 vs last month

Apr Revised Target

328

Base 265 + 63 compounded

Monthly plan vs actual — 2025

Patient targets with compounding gap

Month

Progress

Target

Actual

Gap

Compounded

January

300

261

–39

February

339

280

–59

–98

March

363

263

–100

–126

April ★

328

180 (MTD)

—

Live

Territory breakdown — April

Territory	ZBM	Apr Target	Apr Actual (MTD)	Attainment	Status
Mumbai North	Sneha Patil	48	42	88%	On track
Delhi NCR	Rakesh Verma	52	31	60%	At risk
Bangalore	Divya Krishnan	40	37	93%	On track
Hyderabad	Kiran Reddy	38	28	74%	Watch
Chennai	Anand Suresh	32	22	69%	At risk
Ahmedabad	Preet Shah	36	20	56%	Watch

Top 25% of Doctors

53%

of total NBRX volume

Tier 1 HCPs

186

15% of total base

Tail (Tier 3+)

701

Drives only 12% of Rx

Move-up Targets

94

Tier 3 → Tier 2 potential

Concentration curve — cumulative Rx share

% of total NBRX attributed to top X% of prescribers, sorted by volume

Actual curve

Equality line

25% threshold

50% threshold

Move-up candidates — Tier 3 → Tier 2

Doctors just below the Tier 2 volume threshold

HCP	Territory	Current Tier	Rx YTD	Tier 2 Threshold	Gap to Tier 2	Last Engaged	Action
Dr. Kavitha Nair	Chennai	Tier 3	14	18	–4 Rx	Mar 22	Prioritise
Dr. Nisha Agarwal	Kolkata	Tier 3	13	18	–5 Rx	Mar 10	Engage more
Dr. Suresh Babu	Coimbatore	Tier 3	11	18	–7 Rx	Apr 1	Engage more
Dr. Pallavi Joshi	Jaipur	Tier 3	10	18	–8 Rx	Feb 14	Low priority

Upload your data files to power analytics and insights. Supported formats: Excel (.xlsx), CSV. Files are processed securely and validated automatically.

HCP Master Data

Veeva CRM database export

Required

Drop file here or click to browse

Excel or CSV • Max 50MB

Last uploaded: Apr 1, 2025 by User A

Sales Forecast Data

Actual vs planned targets

Required

Drop file here or click to browse

Excel or CSV • Max 50MB

Last uploaded: Mar 28, 2025 by User B

Secondary Sales Data

Stockist to retailer transactions

Required

Drop file here or click to browse

Excel or CSV • Max 50MB

Last uploaded: Apr 5, 2025 by User C

Market Intelligence

Ipsos market share data

Optional

Drop file here or click to browse

Excel or CSV • Max 50MB

Last uploaded: Never

Upload History

Recent data imports

File Name	Data Type	Uploaded By	Date	Records	Status
hcp_master_apr2025.xlsx	HCP Master	User A	Apr 5, 2025	1,247	✓ Processed
secondary_sales_q1.csv	Secondary Sales	User C	Apr 5, 2025	8,342	✓ Processed
forecast_mar2025.xlsx	Forecast	User B	Mar 28, 2025	384	✓ Processed

Generate and download custom reports with filters. All reports are generated in real-time based on the latest uploaded data.

HCP Performance Report

Detailed prescriber analytics

Territory

Time Period

Brand

Forecast vs Actuals

Plan achievement analysis

Territory

Month

Metric

Market Intelligence

Competitive landscape data

Region

Indication

Quarter

Recent Downloads

Last 10 generated reports

Report Name	Type	Filters Applied	Generated By	Date
HCP_Performance_Apr2025.xlsx	HCP Performance	All Territories • Q1 2025 • Both Brands	User A	Apr 10, 2025
Forecast_vs_Actuals_Mar2025.xlsx	Forecast	Mumbai North • March 2025 • All Metrics	User B	Apr 8, 2025
Market_Intelligence_Q1.xlsx	Market Share	Pan India • NSCLC • Q1 2025	User C	Apr 6, 2025